ESMO Magnitude of Clinical Benefit Scale: Evaluation Forms version 1.0

The ESMO Magnitude of Clinical Benefit Scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from a new anti-cancer treatment

There are four evalutation forms, which can be downloaded below:

Evaluation form 1

For new approaches to adjuvant therapy or new potentially curative therapies

Hyper mature data from studies that were un-blinded after compelling early results with subsequent access to the superior arm are contaminated, subsequently late intention to treat (ITT) follow-up data are not evaluable

Evaluation form 2a

For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:

  • IF median OS with the standard treatment is < 1 year
  • IF median OS with the standard treatment > 1 year

Evaluation form 2b

For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:

  • IF median PFS with standard treatment < 6 months
  • IF median PFS with standard treatment > 6 months

Evaluation form 2c

For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent studies

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings